These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 1617654)

  • 1. Correspondence Re: L.E. Damon et al., Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-D-arabinofuranosylcytosine. Cancer Res., 51: 4141-4145, 1991.
    Kreis W; Budman DR
    Cancer Res; 1992 Jul; 52(13):3818-20. PubMed ID: 1617654
    [No Abstract]   [Full Text] [Related]  

  • 2. Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-D-arabinofuranosylcytosine.
    Damon LE; Plunkett W; Linker CA
    Cancer Res; 1991 Aug; 51(16):4141-5. PubMed ID: 1868435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of the metabolism and pharmacokinetics of 1-beta-D-arabinofuranosylcytosine by 1-beta-D-arabinofuranosyluracil in leukemic mice.
    Chandrasekaran B; Capizzi RL; Kute TE; Morgan T; Dimling J
    Cancer Res; 1989 Jun; 49(12):3259-66. PubMed ID: 2720678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous determination of 1-β-d-Arabinofuranosylcytosine and two metabolites, 1-β-d-Arabinofuranosyluracil and 1-β-d-Arabinofuranosylcytosine triphosphate in leukemic cell by HPLC-MS/MS and the application to cell pharmacokinetics.
    Liang D; Wang W; Jiang X; Yin S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jul; 962():14-19. PubMed ID: 24880220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in patients with acute leukemia.
    Ueda T; Nakamura T; Ando S; Kagawa D; Sasada M; Uchino H; Johno I; Akiyama Y
    Cancer Res; 1983 Jul; 43(7):3412-6. PubMed ID: 6850647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A radioimmunoassay for 1-beta-D-arabinofuranosyluracil with reference to cross-reactivity of 1-beta-D-arabinofuranosylcytosine with an antibody.
    Okabayashi T; Mihara S; Repke DB; Moffatt JG
    Cancer Res; 1977 Sep; 37(9):3132-5. PubMed ID: 18280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine.
    Riccardi R; Chabner B; Glaubiger DL; Wood J; Poplack DG
    Cancer Res; 1982 May; 42(5):1736-9. PubMed ID: 6896013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid and plasma pharmacokinetics of high doses of 1-beta-D-arabinofuranosylcytosine in nonhuman primates.
    Lopez JA; Beardsley GP; Krikorian JG; Mortara RW; Agarwal RP
    Cancer Res; 1983 Nov; 43(11):5190-3. PubMed ID: 6616454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine.
    Liliemark JO; Plunkett W; Dixon DO
    Cancer Res; 1985 Nov; 45(11 Pt 2):5952-7. PubMed ID: 4053067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Degradation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human leukemic myeloblasts and lymphoblasts.
    Jamieson GP; Finch LR; Snook M; Wiley JS
    Cancer Res; 1987 Jun; 47(12):3130-5. PubMed ID: 3472653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological study of modified intermediate-dose cytarabine therapy in patients with acute myeloid leukemia.
    Sutoh H; Yamauchi T; Gotoh N; Sugiyama M; Ueda T
    Anticancer Res; 2003; 23(6D):5037-42. PubMed ID: 14981964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine.
    Ueda T; Kamiya K; Urasaki Y; Wataya S; Kawai Y; Tsutani H; Sugiyama M; Nakamura T
    Cancer Res; 1994 Jan; 54(1):109-13. PubMed ID: 8261429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo studies on high-dose 1-beta-D-arabinofuranosylcytosine (HDara-C) and 1-beta-D-arabinofuranosyluracil (ara-U) with respect to pharmacokinetics, cell kinetics, and cytotoxicity in a rat myelocytic leukemia model (BNML).
    Colly LP; Willemze R; Honders W; vd Hoorn F; Edelbroek PM
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):49-54. PubMed ID: 3859932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A radioimmunoassay method for 1-beta-D-arabinofuranosyluracil using antibodies directed against 1-beta-D-arabinofuranosylcytosine.
    Okabayashi T; Mihara S; Moffatt JG
    Cancer Res; 1977 Feb; 37(2):625-8. PubMed ID: 12864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of tetrahydrouridine on the clinical pharmacology of 1-beta-D-arabinofuranosylcytosine when both drugs are coinfused over three hours.
    Kreis W; Chan K; Budman DR; Schulman P; Allen S; Weiselberg L; Lichtman S; Henderson V; Freeman J; Deere M
    Cancer Res; 1988 Mar; 48(5):1337-42. PubMed ID: 3342412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of differentiation of acute promyelocytic leukemia cells by a cytidine deaminase-resistant analogue of 1-beta-D-arabinofuranosylcytosine, 1-(2-deoxy-2-methylene-beta-D-erythro-pentofuranosyl)cytidine.
    Niitsu N; Ishii Y; Matsuda A; Honma Y
    Cancer Res; 2001 Jan; 61(1):178-85. PubMed ID: 11196157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ
    Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of cell-killing effects of 1-beta-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system.
    Kishi S; Goto N; Nakamura T; Ueda T
    Cancer Res; 1999 Jun; 59(11):2629-34. PubMed ID: 10363985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ion-pair liquid chromatography of cytarabine and uracil-arabinoside in human plasma.
    Burk M; Volmer M; Fartash K; Schneider W
    Arzneimittelforschung; 1995 May; 45(5):616-9. PubMed ID: 7612064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in leukemic cells after intravenous and subcutaneous administration of 1-beta-D-arabinofuranosylcytosine.
    Liliemark JO; Paul CY; Gahrton CG; Peterson CO
    Cancer Res; 1985 May; 45(5):2373-5. PubMed ID: 3986778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.